Sugi Predict

Sugi Predict / Compounds / SCHEMBL2168997

SCHEMBL2168997

SCHEMBL2168997

O=S(=O)(c1ccc(Cl)cc1)N1C2CC(C3(O)CC3)CC1CC1(C2)OCCO1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 4/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ ACHE P22303 1/20 0.39
▸ PSEN1 P49768 1/20 0.39
▸ PSEN2 P49810 1/20 0.39
▸ APH1B Q8WW43 1/20 0.39
▸ NCSTN Q92542 1/20 0.39
▸ APH1A Q96BI3 1/20 0.39
▸ PSENEN Q9NZ42 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ HSD11B1 P28845 2/20 0.38
▸ ATM Q13315 1/20 0.38
▸ MMP2 P08253 3/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ ANPEP P15144 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ CREBBP Q92793 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2184346 0.83 POLB (0.48) POLBSMN1; SMN2ACHEPSEN1PSEN2
SCHEMBL3231510 0.81 POLB (0.56) POLBSMN1; SMN2ACHEPSEN1PSEN2
SCHEMBL2170017 0.76 PSEN1 (0.55) POLBSMN1; SMN2PSEN1PSEN2APH1B
SCHEMBL2186325 0.73 PSEN1 (0.58) POLBSMN1; SMN2ACHEPSEN1PSEN2
SCHEMBL3075003 0.73 POLB (0.52) POLBSMN1; SMN2ACHEPSEN1PSEN2
SCHEMBL3078343 0.73 POLB (0.52) POLBSMN1; SMN2ACHEPSEN1PSEN2
SCHEMBL3075002 0.73 POLB (0.52) POLBSMN1; SMN2ACHEPSEN1PSEN2
SCHEMBL3078347 0.73 POLB (0.52) POLBSMN1; SMN2ACHEPSEN1PSEN2
SCHEMBL3066152 0.71 POLB (0.47) POLBACHEPSEN1PSEN2APH1B
SCHEMBL5306415 0.68 POLB (1.00) POLBSMN1; SMN2KDM4EATMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8283358-B2 N-sulfonamido polycyclic pyrazolyl compounds ELAN PHARMACEUTICALS, INC. (US) 2012-10-09 — — US disclosed
US-8283358-B2 N-sulfonamido polycyclic pyrazolyl compounds ELAN PHARMACEUTICALS, INC. (US) 2012-10-09 — — US disclosed
EP-2346863-A2 N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS Elan Pharmaceuticals Inc. (US) 2011-07-27 — — EP disclosed
US-20100081680-A1 N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS ELAN PHARMACEUTICALS, INC. 2010-04-01 — — US disclosed
US-20100081680-A1 N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS ELAN PHARMACEUTICALS, INC. 2010-04-01 — — US disclosed
WO-2010028213-A2 N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS ELAN PHARMACEUTICALS, INC. (US) 2010-03-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081680-A1 N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS PSEN1, PSEN2, SULT1E1 POLB 4287/4885SMN1; SMN2 101/4885ACHE 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.